July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Molecular footprints of oxidative stress in corneal injuries of different origin: utilization of human organotypic corneal tissue model
Author Affiliations & Notes
  • Yulia Kaluzhny
    MatTek Corporation, Ashland, Massachusetts, United States
  • Miriam Kinuthia
    MatTek Corporation, Ashland, Massachusetts, United States
  • Thoa Truong
    MatTek Corporation, Ashland, Massachusetts, United States
  • Allison Lapointe
    MatTek Corporation, Ashland, Massachusetts, United States
  • Mitchel Klausner
    MatTek Corporation, Ashland, Massachusetts, United States
  • Patrick Hayden
    MatTek Corporation, Ashland, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Yulia Kaluzhny, MatTek Corporation (E); Miriam Kinuthia, MatTek Corporation (E); Thoa Truong, MatTek Corporation (E); Allison Lapointe, MatTek Corporation (E); Mitchel Klausner, MatTek Corporation (E); Patrick Hayden, MatTek Corporation (E)
  • Footnotes
    Support   None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4727. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yulia Kaluzhny, Miriam Kinuthia, Thoa Truong, Allison Lapointe, Mitchel Klausner, Patrick Hayden; Molecular footprints of oxidative stress in corneal injuries of different origin: utilization of human organotypic corneal tissue model. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4727.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Oxidative stress (OS) plays an important role in dry eye disease (DED) and other corneal injuries, including irradiation, chemical burns, and exposure to vesicating agents. Current methods utilize monolayer cell cultures or animals that result in poor data extrapolation, low throughput and high cost. Physiologically relevant, human-based in vitro models for ocular research are needed.

Methods : This study evaluated the utility of an in vitro reconstructed 3D tissue model (EpiCorneal) to study molecular mechanisms of OS corneal damage. The 3D tissues are comprised of normal human corneal epithelial cells that are cultured at the air-liquid interface. They develop a tight barrier (TEER 1000±250 Ω*cm2) and express tight junctions, mucins, and key corneal detoxification enzymes similar to in vivo human cornea. OS was generated by exposure to DED conditions (elevated temperatures and low humidity for 24-72h), irradiation (UVB, 60/120mJ), hydrogen peroxide (HP, 20/50mM), and nitrogen mustard (NM, 7.8mM for 10/30min). Barrier function, tissue viability, reactive oxygen species (ROS) accumulation, lipid oxidation, cytokine release, histology, and gene expression were evaluated 2/24h post-exposure.

Results : The most pronounced effects were as follows. DED: tissue thinning, barrier impairment, decline in mucin expression, and increased lipid oxidation. Topical application of lubricant eye drops improved tissue morphology, barrier, and lipid oxidation. UVB: intracellular ROS accumulation. HP: barrier impairment and decreased tissue viability, morphology deterioration 24h post-incubation of 50mM-treated tissues. NM: barrier impairment, decreased tissue viability, lipid oxidation, IL-8 release, and tissue morphology deterioration 24h post-incubation. Utilizing a PCR gene array, we compared effects of corneal damage on the expression of 84 OS responsive genes (antioxidants, ROS and superoxide metabolism, oxygen transport and others), and found specific molecular footprints for each mechanism of OS corneal damage.

Conclusions : In summary, the in vitro 3D corneal tissues structurally and functionally reproduced key features of in vivo cornea and unique toxicity and molecular responses for various types of OS ocular damage. This model is anticipated to be a useful tool to study molecular mechanisms of DED and corneal damage and to evaluate new corneal drug formulations.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×